Overview of Telfast Plus

What is Telfast Plus? (Fexofenadine and Pseudoephedrine Combination)

Property	Description
Active Ingredients	Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride
Form	Oral Extended-Release Tablet
Pharmacological Class	Antihistamine-Decongestant Combination
Common Use	Simultaneous relief of allergic rhinitis symptoms and nasal congestion
Origin	Synthetic

What Type of Medicine is Telfast Plus? (Identity and Classification)

Telfast Plus is classified as a fixed-dose combination (FDC) product, categorized pharmacologically as an Antihistamine-Decongestant Combination medicine. This medicine is designed for systemic relief from allergy and congestion symptoms simultaneously. The core components are synthetic in origin and are commonly marketed under the brand Telfast Plus by Sanofi-Aventis, though the same formulation is widely available internationally under its generic name or other brands.

Active Ingredients, Composition, and Form (Substance and Presentation)

The two essential active ingredients are Fexofenadine Hydrochloride, a second-generation antihistamine, and Pseudoephedrine Hydrochloride, a sympathomimetic amine decongestant. The medicine is delivered in an oral tablet that utilizes an extended-release system. This extended-release feature is specifically engineered to ensure the two agents are absorbed systemically and maintain consistent therapeutic concentrations over a prolonged period for simplified patient administration.

The Core Benefit of Dual-Action Relief (General Purpose)

This medication's primary benefit is its capacity to deliver dual-action relief by simultaneously targeting the allergic mechanism and the resultant nasal blockage, typical in cases of seasonal allergic rhinitis. This synergistic effect is achieved through the two component actions. Fexofenadine ensures histamine blockade to reduce irritation, while Pseudoephedrine narrows the blood vessels in the nasal mucosa to reduce mucosal edema and the uncomfortable sensation of nasal congestion. This combination provides an effective strategy for patients needing simultaneous relief from both allergy symptoms and airway obstruction.

What side effects are possible with Telfast Plus?

Possible Side Effects and Safety Information

The safety profile of Telfast Plus, which contains the antihistamine fexofenadine and the decongestant pseudoephedrine, is based on data collected from clinical trials and post-marketing surveillance as classified by regulatory authorities.

Adverse Reaction Frequency

Adverse reactions are formally categorized by frequency to show how often they occur based on the available data:

Common (may affect up to 1 in 10 people): Headache, drowsiness, dizziness, and nausea.
Uncommon (may affect up to 1 in 100 people): Fatigue.
Not Known (frequency cannot be estimated from the available data): This category includes reports of insomnia, nervousness, sleep disorders, nightmares, blurred vision, diarrhoea, tachycardia, palpitations, rash, urticaria, pruritus, and serious hypersensitivity reactions.

Serious Adverse Reactions

While generally rare, serious adverse reactions have been reported, primarily as part of hypersensitivity reactions. These include anaphylaxis (a severe, life-threatening allergic reaction) and angioedema (rapid swelling beneath the skin, often in the face). Patients should immediately discontinue use and seek medical attention if signs of a severe allergic reaction occur.

Safety Restrictions and Special Populations

Contraindications: Use is restricted in patients with known hypersensitivity to the active ingredients or excipients.
Cardiac Concerns: Caution is advised for patients with existing cardiovascular disease due to reports of palpitations and tachycardia (rapid heart rate).
Renal Impairment: Caution is recommended in patients with reduced kidney function, as the medication is primarily excreted by the kidneys.
Pregnancy and Lactation: Use during pregnancy is generally advised only if the potential benefit outweighs the potential risk to the fetus.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of the Fexofenadine and Pseudoephedrine combination involves potential manifestations from both active ingredients. Overdosage related to fexofenadine may present with central nervous system effects such as dizziness, drowsiness, and dry mouth. Overdose effects from pseudoephedrine are typically associated with stimulation of the central nervous system and cardiovascular system. These symptoms can include excitement, restlessness, hallucinations, hypertension (high blood pressure), and cardiac arrhythmias.

Severe outcomes documented in regulatory sources include the risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS), which are characterized by sudden severe headache, seizures, and confusion. Patients with severe acute or chronic kidney disease or uncontrolled hypertension are considered at increased risk for these severe pseudoephedrine-related outcomes.

Immediate medical attention or contacting a Poison Control Center is required in the event of a suspected overdose. Urgent medical help must be sought if severe neurological symptoms or rapid heart rate occur. Treatment is symptomatic and supportive, as no specific antidote is known for fexofenadine, and hemodialysis is not effective for its removal. Cardiac monitoring may be necessary in cases of large overdose.

Therapeutic Uses of Telfast Plus

Quick Facts

Condition addressed: Seasonal allergic rhinitis (hay fever).
Relief provided: May help relieve symptoms of upper respiratory allergies, including nasal congestion and pressure.
Key symptom relief: May help reduce sneezing, runny nose, itchy throat or nose, and watery eyes.

What Telfast Plus Treats: Main Uses and Benefits

Telfast Plus is indicated for the temporary relief of common upper respiratory symptoms associated with seasonal allergic rhinitis, often known as hay fever. This combination product works to address both the histamine-related and congestion-related effects of allergies.

For individuals experiencing seasonal allergies, the medication may help alleviate a range of discomforts. Its uses include relief from sneezing, runny nose, itchy nose or throat, and the presence of itchy, watery eyes. Furthermore, the decongestant component works to relieve symptoms of nasal congestion and sinus pressure, which are often present with hay fever.

Clinical guidance suggests that this type of treatment may be appropriate when both antihistamine and nasal decongestant actions are desired to manage the full spectrum of seasonal allergy symptoms. The combination of ingredients contributes to freer breathing by reducing swelling of nasal passages.

Regulatory References

NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

Telfast Plus (Fexofenadine/Pseudoephedrine combination) is subject to strict eligibility rules defined by government regulatory authorities.

Population Status	Regulatory Wording (Summary)
Eligible Age Group	Adults and adolescents 12 years of age and older [1.1, 1.2]
Ineligible Age Group	Children under 12 years (Do not use / Safety and effectiveness not established) [1.1, 1.7]
Absolute Contraindications	Patients with severe or uncontrolled hypertension, severe coronary artery disease, or narrow-angle glaucoma [1.2, 1.5]
	Patients with known hypersensitivity to any ingredient or concurrent use of a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of stopping MAOI therapy [1.5, 2.1]
Conditional Use/Caution	Patients with kidney disease or decreased renal function; a doctor should determine if a different dose is needed [1.3, 2.1]
	Older adults (ge 65 years); they should ask a doctor due to increased risk of side effects [1.3, 2.1]
Pregnancy/Lactation	Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus [1.5]. Lactation: Not recommended for nursing women [1.5].

These rules define the mandatory boundaries for the medicine's use, establishing who must be excluded (contraindicated) and who requires prior medical evaluation (conditional use).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for the Fexofenadine and Pseudoephedrine combination is formally documented across several categories. Contraindicated combinations include Monoamine Oxidase Inhibitors (MAOIs), which must not be co-administered, nor within 14 days of cessation, due to the documented risk of severe hypertensive reactions. Ergot Derivatives are also contraindicated for the same risk of enhanced vasoconstriction.

Pharmacokinetic interactions primarily involve the Fexofenadine component. Substances that inhibit P-glycoprotein (P-gp) transporters, such as Erythromycin or Ketoconazole, are documented to cause a significant increase in fexofenadine's plasma concentration and systemic exposure. Conversely, P-gp inducers can decrease fexofenadine exposure.

Pharmacodynamic interactions stem from the Pseudoephedrine component. Co-administration with other sympathomimetic agents can lead to additive effects, and pseudoephedrine may inhibit the therapeutic effect of certain antihypertensive medications, including beta-blockers.

Timing and Absorption Constraints are essential for effective use. Antacids containing Aluminum or Magnesium Hydroxide must be separated from this medicine by at least two hours to prevent reduced absorption of fexofenadine. Furthermore, the regulatory labeling advises avoiding specific fruit juices (e.g., grapefruit, apple, orange) as they are documented to reduce fexofenadine bioavailability. Alkalinizing agents may also decrease the elimination rate of pseudoephedrine, increasing the risk of accumulation, a risk also noted for patients with decreased renal function.

Mechanism of Action

How Telfast Plus Works: Mechanism of Action

Peripheral Blockade of Histamine Signaling

This mechanism covers Fexofenadine's action as a selective H1 receptor antagonist. By binding to and stabilizing these peripheral receptors in an inactive conformation, the drug inhibits the signaling cascade initiated by endogenous histamine release. This physiological effect reduces the mediator-driven increase in capillary permeability and the resulting stimulation of sensory nerves. Fexofenadine demonstrates minimal blood-brain barrier penetration, focusing its H1 blockade on peripheral tissues.

Targeted Sympathomimetic Control of Nasal Blood Flow

This domain focuses on Pseudoephedrine's role as a sympathomimetic amine, primarily through alpha1-adrenergic receptor activation. This action causes the smooth muscles of nasal blood vessels to contract (vasoconstriction), which lowers local blood flow and volume. This mechanism results in the functional reduction of mucosal edema and tissue volume within the nasal and sinus passages.

The combined formulation operates through dual-system modulation, affecting the allergic inflammatory pathway and the autonomic vascular pathway simultaneously. This approach addresses the molecular mechanism (histamine action) and the resulting physical change (tissue swelling) via two core, distinct physiological processes.

Dosage and Administration Information

How to Use Telfast Plus: Official Administration Guidelines

Administration of Telfast Plus (Fexofenadine and Pseudoephedrine Extended-Release Tablets) follows standardized protocols to ensure the drug's intended action over time. The medicine is classified for oral administration.

Standard Dosing and Frequency

Formulation Strength	Adult Dosing Regimen	Frequency
12-Hour (60 mg / 120 mg)	One tablet	Twice daily (every 12 hours)
24-Hour (180 mg / 240 mg)	One tablet	Once daily (every 24 hours)

The maximum recommended daily pseudoephedrine dose is 240 mg. The medication is officially intended for temporary relief and not for indefinite long-term use.

Procedural Administration Constraints

The extended-release formulation requires specific intake conditions to maintain the tablet's integrity and facilitate proper absorption. The tablet must be swallowed whole and must not be divided, crushed, broken, or chewed. Administration is typically advised on an empty stomach—such as one hour before or two hours after a meal—and with water.

Key dietary constraints restrict intake with certain substances: the tablet must not be taken with fruit juices (e.g., grapefruit, orange, apple) nor with antacids containing aluminum or magnesium, as these substances may interfere with fexofenadine absorption.

Population-Specific Use

High-level usage adjustments are noted for certain populations. Patients with decreased kidney function are typically instructed to reduce the frequency of the 12-hour formulation to one tablet once daily. In the event of a missed dose, the official instruction is to take the next dose at the next regularly scheduled time; a patient should not double the dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Telfast Plus

Evidence for Use in Seasonal Allergic Rhinitis

Research exploring this fixed-dose combination was studied for use in adults and adolescents facing the full range of episodic symptom patterns associated with seasonal allergic rhinitis, commonly known as hay fever. The core evidence is derived from short-term, randomized controlled trials (RCTs). These studies were designed to examine the combination medicine against a placebo (an inactive substance) and against the two components taken individually. Outcomes related to patient-reported outcomes describing perceived discomfort were key, often using scores that track changes in physical discomfort such as sneezing, runny nose, and the overall feeling of stuffiness.

Studies describe patterns where outcomes related to perceived discomfort were measured across groups receiving the combination product and those receiving placebo over the short-term observation period. The evidence contributes to the broader understanding of symptom patterns relevant in trials assessing short-term or episodic symptom patterns.

Evidence for Relief of Nasal Congestion

Separate research has examined the decongestant component, specifically for its role in addressing nasal obstruction, which is a key symptom of allergic rhinitis. Studies explored outcomes related to systemic or functional imbalance in the nasal passages. This research often uses specialized, ultra-short-term trials, where studies monitored responses over defined time intervals. Research examined measures of nasal airflow using objective measures, in addition to collecting patient-reported outcomes describing perceived discomfort. Research describes how the decongestant component was observed in relation to these measurements when compared to the antihistamine component administered alone.

Long-Term Studies and Follow-Up Data

When evaluating any combination medicine, one important consideration is the duration of the clinical trials. The primary evidence for this combination is relevant in trials assessing short-term or episodic symptom patterns, typically lasting only one to two weeks. These short study periods provide context to understanding research exploring short-term symptom changes. Long-term effects are not fully established because data are still emerging and follow-up durations were limited in the pivotal trials. Consequently, research exploring chronic or ongoing use of the combination is an area where certainty remains low.

Research Gaps and Areas of Uncertainty

A key gap involves the limited information for long-term outcomes regarding the repeated or chronic use of the combination, as the majority of studies were designed for short-term observation. Additionally, data for certain groups remain insufficient, such as for patients with specific comorbidities or those outside the studied age ranges. These limitations mean that findings describe group patterns, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Telfast Plus (FAQ)

Q: What is the difference between regular Telfast and Telfast Plus?

According to official product information, Telfast Plus is classified as a fixed-dose combination (FDC) medicine. This means it contains two active ingredients: Fexofenadine (an antihistamine) and Pseudoephedrine (a decongestant). The 'Plus' typically refers to the addition of the decongestant component to the original formulation, which generally contains only Fexofenadine.

Q: How quickly should Telfast Plus start working after I take it?

Studies indicate that the antihistamine component of the combination tablet begins to take effect within approximately one hour after administration. It typically reaches its maximum concentration in the blood around two hours post-dose. The two ingredients are designed to provide simultaneous relief from both allergy symptoms and nasal congestion.

Q: Can Telfast Plus be used for treating a regular cold or flu?

The official product information indicates that this medication is approved for the relief of symptoms associated with allergic rhinitis (such as hay fever), specifically when both the antihistamine and nasal decongestant properties are needed. The approved use is focused on symptoms caused by allergic reactions.

Q: Can Telfast Plus be taken alongside common pain relievers like paracetamol?

Official product labeling generally advises informing a healthcare professional when taking the drug with other medications, including common painkillers. This caution is generally due to the risk of exceeding the recommended daily limits of one or more active ingredients when combining multiple products.

Q: Why is Telfast Plus sometimes kept behind the counter at pharmacies?

The ingredient Pseudoephedrine, a decongestant found in Telfast Plus, is often subject to specific governmental regulations in various jurisdictions. These regulations may restrict how the product is sold, sometimes requiring it to be kept behind the pharmacy counter to monitor or track sales and limit purchase quantities.

Q: Is it normal if my mouth feels dry while I am taking Telfast Plus?

Yes, dry mouth has been reported as a side effect associated with the use of this combination medication. Official consumer information notes that this and other side effects may occur during use.

Q: Can I take Telfast Plus if I have been diagnosed with an anxiety disorder?

The pseudoephedrine component of this medicine is a sympathomimetic amine, which can stimulate the central nervous system. This may result in side effects such as nervousness, excitability, or anxiety. Regulatory labeling notes the importance of discussing pre-existing medical conditions with a healthcare professional.

Q: Are there known interactions between Telfast Plus and herbal supplements?

Official drug interaction lists focus on prescription medicines, over-the-counter products, and certain food items. There is generally not enough comprehensive clinical data to definitively state the safety of combining this medication with all herbal remedies or supplements. Official patient information describes that a full list of all supplements being taken should be shared with a healthcare professional.

Q: Does Telfast Plus affect fertility or reproductive health?

Official documents state that there are no specific clinical studies available in humans that have evaluated the effects of the combination product on fertility. Preclinical safety data, derived from animal studies at high exposure levels, has examined effects on reproductive metrics; however, these findings do not necessarily translate to human experience.

Q: Can Telfast Plus be used for skin allergies like hives?

The combination product’s approved use, as described in regulatory documents, is specific to the symptoms of allergic rhinitis with nasal congestion. This includes symptoms associated with hay fever.

Q: Do regulatory bodies classify Telfast Plus as a restricted substance?

Regulatory bodies classify the ingredient Pseudoephedrine as a controlled or regulated substance in several regions. This classification leads to retail restrictions on products containing the ingredient, often including purchase limits or required pharmacist tracking.

Q: Why are people often told to check with a pharmacist before buying Telfast Plus?

Official regulatory labels include statements indicating that a healthcare professional should be consulted if the individual has certain underlying conditions, such as heart disease or diabetes, or if they are taking other medications. Additionally, the Pseudoephedrine component often necessitates pharmacist oversight at the point of purchase.

Q: Is the onset of action faster for the antihistamine part or the decongestant part?

Pharmacokinetic studies show that the active ingredients are absorbed at different rates. The antihistamine component (fexofenadine) typically reaches its maximum concentration in the blood around 2 hours after dosing. In contrast, the decongestant component (pseudoephedrine) reaches its maximum concentration later, generally around 5 to 6 hours after dosing.

Q: Is Telfast Plus suitable for people with diabetes?

Official labeling includes a specific warning that the pseudoephedrine component is a sympathomimetic amine and requires judicious use in patients with diabetes mellitus. Given this potential interaction, regulatory documents note that consultation with a healthcare professional is important for individuals with diabetes.

Q: Are there any warnings about using Telfast Plus before a medical procedure?

Official patient information includes statements that individuals should share a full list of their medications, including this one, with their healthcare providers. This is particularly important if they are scheduled for any type of surgery or procedure that involves a general anaesthetic.

How should Telfast Plus be stored and disposed of?

How to Store and Dispose of Telfast Plus?

Storage Requirements

Telfast Plus (fexofenadine and pseudoephedrine) must be stored at controlled room temperature, specifically between 20^circ to 25 C (68^circ to 77 F). The medication must be protected from environmental factors by storing it away from excess heat, light, and moisture; therefore, storage in a bathroom is discouraged. Always keep the medicine in the container it came in, tightly closed. Do not use the tablets after the expiry date printed on the packaging.

Child Safety and Disposal

It is mandatory to store this medication out of the sight and reach of children in a secure, up and away location. For disposal, unused or expired Telfast Plus must not be thrown away via household waste or wastewater. Consult a pharmacist or use a formal medicine take-back program to ensure appropriate environmental protection.

Telfast Plus